Fennec Pharmaceuticals Inc. (FENC)
FENC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$10.18
-5.04% on the day
Market cap
$356.6M
Small cap
Revenue · 2025
$44.6M
-6.1% on 2024
Net income · 2025
-$9.7B
-21820.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | FENC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001211583 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | A1 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $44.6M |
| Net income | -$9.7B |
| Operating income | -$6.3M |
| Net margin | -21820.3% |
| Operating margin | -14.1% |
| Revenue growth | -6.1% |
| Cash | $36.8M |
| Total assets | $70.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-18 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-09-17 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 847 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.8% |
| 1 month | -4.4% |
| 3 months | -2.5% |
| Year to date | +32.1% |
| 1 year | +20.6% |
| From 52-week high | -20.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KYTX | Kyverna Therapeutics Inc. | $5.77 | -7.08% | $356.8M |
| SCTX | Scribe Therapeutics Inc. | $19.12 | -7.50% | $362.0M |
| EIKN | Eikon Therapeutics Inc. | $6.72 | -7.44% | $364.0M |
| CCCC | C4 Therapeutics Inc. | $2.78 | -9.15% | $342.0M |
| TRXB | TRex Bio Inc. | $13.60 | -3.06% | $373.3M |
| EDIT | Editas Medicine Inc. | $2.44 | -11.09% | $375.5M |
| AGEN | Agenus Inc. | $6.95 | -6.46% | $313.9M |
| ZURA | Zura Bio Limited | $4.23 | +5.75% | $405.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier